ロード中...
Targeting HER2(+) breast cancer: the TBK1/IKKε axis
HER2(+) breast cancer (BC) is a highly aggressive subtype, affecting ~20% of BC patients. Current treatments include adjuvant or neoadjuvant chemotherapy plus anti-HER2 agents such as trastuzumab, a monoclonal antibody directed against HER2. Despite improvement in disease free survival, most patient...
保存先:
| 出版年: | Oncoscience |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4278282/ https://ncbi.nlm.nih.gov/pubmed/25594009 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|